Keymed Biosciences' Stapokibart Receives NMPA Approval for Seasonal Allergic Rhinitis and Chronic Rhinosinusitis with Nasal Polyposis
• Keymed Biosciences' Stapokibart (Kangyueda) has been approved by China's NMPA for seasonal allergic rhinitis, expanding its therapeutic applications.
• Phase III trial data showed Stapokibart significantly reduced nasal symptoms and improved quality of life compared to standard treatments for allergic rhinitis.
• Stapokibart also received approval for chronic rhinosinusitis with nasal polyposis (CRSwNP) based on statistically significant improvements in nasal polyp score and congestion.
• Stapokibart, a humanized anti-IL-4Rα monoclonal antibody, is the first domestically manufactured drug of its kind approved in China.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath